




# PHARMACEUTICAL 2023

Aravive Inc.  
Rank 359 of 446





# PHARMACEUTICAL 2023

Aravive Inc.  
Rank 359 of 446



The relative strengths and weaknesses of Aravive Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Aravive Inc. compared to the market average is the variable Selling, General and Administrative Expense, increasing the Economic Capital Ratio by 18% points. The greatest weakness of Aravive Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is -102%, being 145% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	57,970
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	22,112
Liabilities, Non-Current	2,503
Other Assets	3,913
Other Compr. Net Income	0
Other Expenses	8,981
Other Liabilities	26,881
Other Net Income	3,496
Other Revenues	9,137
Property and Equipment	270
Research and Development	66,938
Selling, General and Administrative Expense	13,036

Output Variable	Value in 1000 USD
Assets	62,153
Liabilities	51,496
Expenses	88,955
Revenues	9,137
Stockholders Equity	10,657
Net Income	-76,322
Comprehensive Net Income	-76,322
Economic Capital Ratio	-102%